COVID-19: Long-Term Considerations For Biologics, Biosimilar Makers

The COVID-19 pandemic has thrown the entire pharmaceutical industry, as well as patients, providers, and sites of care for a loop. Though small molecule novel treatments and generics have seen much more pronounced impacts from market shut-downs and supply-chain disruptions, the biologics and biosimilars industry has also been striving to understand how the pandemic will alter availability and usage of biologic products. This collection of articles surveys a wide array of considerations facing biopharma and biosimilar companies, including the pandemic's impact on regulatory interactions, product supply and demand, materials sourcing, and market access and uptake.

- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
Not yet a member of Biosimilar Development? Register today.